Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma
Department of Ophthalmology, University Hospital of Heraklion, Crete, Greece
Department of Radiation Physics, University Hospital of Heraklion, Crete, Greece
Medical School, European University of Cyprus, Cyprus
J Contemp Brachytherapy 2026; 18, 2
Data publikacji online: 2026/06/11
Article file
- Shields CL, Markowitz JS, Belinsky I et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 2011; 118: 389-395.e1-2.
Patel U, Karp CL, Dubovy SR. Update on the management of ocular surface squamous neoplasia. Curr Ophthalmol Rep 2021; 9: 7-15.
Cicinelli MV, Marchese A, Bandello F et al. Clinical management of ocular surface squamous neoplasia: a review of the current evidence. Ophthalmol Ther 2018; 7: 247-262.
Wong JR, Nanji AA, Galor A et al. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol 2014; 9: 185-204.
Pfeiffer ML, Ozgur OK, Myers JN et al. Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmol 2017; 95: e323-e328.
Carlà MM, Sammarco MG, Giannuzzi F et al. Exclusive Ru-106 brachytherapy for the management of a recurrent corneo-conjunctival squamous cell carcinoma. Brachytherapy 2024; 23: 457-462.
Bonnell AC, Selby LD, Nguyen MT et al. Adjuvant brachy- therapy using iodine-125 plaques for conjunctival melanoma with scleral invasion. Semin Ophthalmol 2025; 40: 546-550.
Walsh-Conway N, Conway RM. Plaque brachytherapy for the management of ocular surface malignancies with corneoscleral invasion. Clin Exp Ophthalmol 2009; 37: 577-583.
Cohen VML, Papastefanou VP, Liu S et al. The use of strontium-90 beta radiotherapy as adjuvant treatment for conjunctival melanoma. J Oncol 2013; 2013: 349162.
Berkowitz ST, Brock AL, Astrahan MA et al. Annulus-shaped I-125 plaque brachytherapy for conjunctival melanoma. Am J Ophthalmol Case Rep 2022; 26: 101512.
Arepalli S, Kaliki S, Shields CL et al. Plaque radiotherapy in the management of scleral-invasive conjunctival squamous cell carcinoma: an analysis of 15 eyes. JAMA Ophthalmol 2014; 132: 691-696.
Karimi S, Arabi A, Shahraki T. Plaque brachytherapy in iris and iridociliary melanoma: a systematic review of efficacy and complications. J Contemp Brachytherapy 2021; 13: 46-50.
Fionda B, Pagliara MM, Lancellotta V et al. Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): visual atlas and literature review on response assessment. J Contemp Brachytherapy 2022; 14: 96-106.
Chevli N, Zuhour RJ, Messer JA et al. Contemporary trends in management of uveal melanoma. J Contemp Brachytherapy 2022; 14: 123-129.
Zwolińska E, Główka L, Chicheł A et al. Ruthenium brachytherapy for iris melanoma. J Contemp Brachytherapy 2023; 15: 344-349.
Mularska W, Chicheł A, Rospond-Kubiak I. Radiation retinopathy following episcleral brachytherapy for intraocular tumors: Current treatment options. J Contemp Brachytherapy 2023; 15: 372-382.
Markiewicz A, Skórkiewicz K, Bogdał A et al. Ophthalmic applicator displacement as a method of treating large diffuse uveal melanomas. J Contemp Brachytherapy 2023; 15: 184-190.
Rao R, Honavar SG, Lahane S et al. Histopathology-guided management of ocular surface squamous neoplasia with corneal stromal or scleral invasion using ruthenium-106 plaque brachytherapy. Br J Ophthalmol 2023; 107: 621-626.
Grajewski L, Kneifel C, Wösle M et al. Adjuvant brachytherapy with ruthenium-106 to reduce the risk of recurrence of conjunctival melanoma after excision. Ocul Oncol Pathol 2024; 10: 162-167.
Churchill RA, Yu CY, Wang KY et al. Clinical features and outcomes of melanoma involving eyelid and conjunctiva. Can J Ophthalmol 2026; 61: 90-98.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
